Advertisement

LncRNA SNHG3 promotes cell proliferation and invasion through the miR-384/hepatoma-derived growth factor axis in breast cancer

Abstract

Long noncoding RNAs (lncRNAs) have been found to be abnormally expressed in cancer, and lncRNA small nucleolar RNA host genes (SNHGs) play critical roles in tumour progression. SNHG3 has been identified as an oncogene in multiple tumour types. However, the role of SNHG3 in breast cancer has not been reported. In this study, we found that SNHG3 was upregulated and associated with tumour malignancy in patients with breast cancer. SNHG3 knockdown inhibited the growth and metastatic capabilities of breast cancer cells in vitro and vivo. We used bioinformatics prediction and functional assay validation to determine that SNHG3 upregulation inhibited miR-384 activity and led to hepatoma-derived growth factor (HDGF) overexpression in breast cancer cells. The findings of this study show that SNHG3 functions as an oncogene in breast cancer and promotes breast cancer cell proliferation and invasion by regulating the miR-384/HDGF axis. The present study might provide a new target for the treatment of breast cancer.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.

  2. 2.

    Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–8. https://doi.org/10.1007/s12013-014-0459-6.

  3. 3.

    Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016;472(1):262–9. https://doi.org/10.1016/j.bbrc.2016.02.102.

  4. 4.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

  5. 5.

    Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18. https://doi.org/10.1038/nrc.2017.99.

  6. 6.

    Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. https://doi.org/10.1038/nrg.2015.10.

  7. 7.

    Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65(6):1140–51. https://doi.org/10.1016/j.eururo.2013.12.003.

  8. 8.

    Zhang A, Xu M, Mo YY. Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol. 2014;6(3):181–91. https://doi.org/10.1093/jmcb/mju013.

  9. 9.

    Cheng J, Chen J, Zhang X, Mei H, Wang F, Cai Z. Overexpression of CRNDE promotes the progression of bladder cancer. Biomed Pharmacother. 2018;99:638–44. https://doi.org/10.1016/j.biopha.2017.12.055.

  10. 10.

    Sun MD, Zheng YQ, Wang LP, Zhao HT, Yang S. Long noncoding RNA UCA1 promotes cell proliferation, migration and invasion of human leukemia cells via sponging miR-126. Eur Rev Med Pharmacol Sci. 2018;22(8):2233–45. https://doi.org/10.26355/eurrev_201804_14809.

  11. 11.

    Zhu Y, Qiao L, Zhou Y, Ma N, Wang C, Zhou J. Long non-coding RNA FOXD2-AS1 contributes to colorectal cancer proliferation through its interaction with microRNA-185-5p. Cancer Sci. 2018;109(7):2235–42. https://doi.org/10.1111/cas.13632.

  12. 12.

    Gu J, Wang Y, Wang X, Zhou D, Zhou M, He Z. Effect of the LncRNA GAS5-MiR-23a-ATG3 axis in regulating autophagy in patients with breast cancer. Cell Physiol Biochem. 2018;48(1):194–207. https://doi.org/10.1159/000491718.

  13. 13.

    Zhang Y, Li J, Jia S, Wang Y, Kang Y, Zhang W. Down-regulation of lncRNA-ATB inhibits epithelial-mesenchymal transition of breast cancer cells by increasing miR-141-3p expression. Biochem Cell Biol. 2019;97(2):193–200. https://doi.org/10.1139/bcb-2018-0168.

  14. 14.

    Zhang T, Cao C, Wu D, Liu L. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumour Biol. 2016;37(2):2379–85. https://doi.org/10.1007/s13277-015-4052-4.

  15. 15.

    Hong L, Chen W, Wu D, Wang Y. Upregulation of SNHG3 expression associated with poor prognosis and enhances malignant progression of ovarian cancer. Cancer Biomark. 2018;22(3):367–74. https://doi.org/10.3233/CBM-170710.

  16. 16.

    Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–83. https://doi.org/10.1038/nrg.2016.20.

  17. 17.

    Song H, Rao Y, Zhang G, Kong X. MicroRNA-384 inhibits the growth and invasion of renal cell carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res. 2018;26(3):457–66. https://doi.org/10.3727/096504017X15035025554553.

  18. 18.

    Fan N, Zhang J, Cheng C, Zhang X, Feng J, Kong R. MicroRNA-384 represses the growth and invasion of non-small-cell lung cancer by targeting astrocyte elevated gene-1/Wnt signaling. Biomed Pharmacother. 2017;95:1331–7. https://doi.org/10.1016/j.biopha.2017.08.143.

  19. 19.

    Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(5):561–4. https://doi.org/10.1200/JCO.2016.71.0947.

  20. 20.

    Jin Y, Feng SJ, Qiu S, Shao N, Zheng JH. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2017;21(14):3176–84.

  21. 21.

    Yang Y, Yang H, Xu M, Zhang H, Sun M, Mu P, et al. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Hum Cell. 2018;31(3):232–41. https://doi.org/10.1007/s13577-018-0206-1.

  22. 22.

    Cao X, Xu J, Yue D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther. 2018;25(1–2):10–7. https://doi.org/10.1038/s41417-017-0006-x.

  23. 23.

    Gao F, Feng J, Yao H, Li Y, Xi J, Yang J. LncRNA SBF2-AS1 promotes the progression of cervical cancer by regulating miR-361-5p/FOXM1 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):776–82. https://doi.org/10.1080/21691401.2019.1577883.

  24. 24.

    Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–61. https://doi.org/10.1038/nm.3981.

  25. 25.

    Deng R, Liu B, Wang Y, Yan F, Hu S, Wang H, et al. High expression of the newly found long noncoding RNA Z38 promotes cell proliferation and oncogenic activity in breast cancer. J Cancer. 2016;7(5):576–86. https://doi.org/10.7150/jca.13117.

  26. 26.

    Ding Z, Ye P, Yang X, Cai H. LncRNA FBXL19-AS1 promotes breast cancer cells proliferation and invasion via acting as a molecular sponge to miR-718. Biosci Rep. 2019. https://doi.org/10.1042/BSR20182018.

  27. 27.

    Zheng S, Jiang F, Ge D, Tang J, Chen H, Yang J, et al. LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma. Biomed Pharmacother. 2019;112:108695. https://doi.org/10.1016/j.biopha.2019.108695.

  28. 28.

    Zhang PF, Wang F, Wu J, Wu Y, Huang W, Liu D, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J Cell Physiol. 2019;234(3):2788–94. https://doi.org/10.1002/jcp.27095.

  29. 29.

    Huang W, Tian Y, Dong S, Cha Y, Li J, Guo X, et al. The long non-coding RNA SNHG3 functions as a competing endogenous RNA to promote malignant development of colorectal cancer. Oncol Rep. 2017;38(3):1402–10. https://doi.org/10.3892/or.2017.5837.

  30. 30.

    Chen E, Xu X, Liu R, Liu T. Small but heavy role: microRNAs in hepatocellular carcinoma progression. Biomed Res Int. 2018;2018:6784607. https://doi.org/10.1155/2018/6784607.

  31. 31.

    Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169–76. https://doi.org/10.1016/j.bbagrm.2015.06.015.

  32. 32.

    Zhang Y, Liu X, Li Q. lncRNA LINC00460 promoted colorectal cancer cells metastasis via miR-939-5p sponging. Cancer Manag Res. 2019;11:1779–89. https://doi.org/10.2147/CMAR.S192452.

  33. 33.

    Du S, Hu W, Zhao Y, Zhou H, Wen W, Xu M, et al. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Cancer Biomark. 2019;24(3):269–77. https://doi.org/10.3233/CBM-182216.

  34. 34.

    Wang G, Pan J, Zhang L, Wei Y, Wang C. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell Prolif. 2017. https://doi.org/10.1111/cpr.12389.

  35. 35.

    Sun H, He L, Ma L, Lu T, Wei J, Xie K, et al. LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer. Oncotarget. 2017;8(66):110552–65. https://doi.org/10.18632/oncotarget.22819.

  36. 36.

    Bai PS, Xia N, Sun H, Kong Y. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma. J Cell Mol Med. 2017;21(11):3023–43. https://doi.org/10.1111/jcmm.13213.

  37. 37.

    Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL, Wang SY, et al. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget. 2016;7(51):84826–38. https://doi.org/10.18632/oncotarget.12704.

  38. 38.

    Eom S, Kim Y, Park D, Lee H, Lee YS, Choe J, et al. Histone deacetylase-3 mediates positive feedback relationship between anaphylaxis and tumor metastasis. J Biol Chem. 2014;289(17):12126–44. https://doi.org/10.1074/jbc.M113.521245.

  39. 39.

    Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C, et al. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 Axis. Mol Ther. 2016;24(7):1199–215. https://doi.org/10.1038/mt.2016.71.

  40. 40.

    Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994;269(40):25143–9.

  41. 41.

    Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989;183(3):273–84.

  42. 42.

    Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial–mesenchymal transition. J Pathol. 2012;228(2):158–69. https://doi.org/10.1002/path.3988.

  43. 43.

    Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao C, et al. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep. 2011;26(2):511–7. https://doi.org/10.3892/or.2011.1295.

Download references

Acknowledgements

This work was supported by the Medicine and Health Science Technology Development Projects of Shandong Province (No. 2016WSO749).

Author information

Correspondence to Wei Hu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethical consent was granted from the Medical Ethics Committee of Zibo Central Hospital for studies involving patients. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Ethical approval of the animal study was granted by the Animal Ethics Committee of Zibo Central Hospital.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ma, Q., Qi, X., Lin, X. et al. LncRNA SNHG3 promotes cell proliferation and invasion through the miR-384/hepatoma-derived growth factor axis in breast cancer. Human Cell 33, 232–242 (2020) doi:10.1007/s13577-019-00287-9

Download citation

Keywords

  • LncRNA SNHG3
  • Breast cancer
  • miR-384
  • Proliferation
  • Invasion